INGRID NTIEGE: Open Payments
NPI 1811679855 · HANOVER, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,128 in 30 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $201 · 2025 $1,128
Food & beverage: $1,122Education: $5
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 6 | $338 |
| Neurocrine BioSciences, Inc. | 7 | $251 |
| Janssen Pharmaceuticals, Inc | 5 | $224 |
| Indivior Inc. | 3 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Lundbeck LLC | 3 | $73 |
| Luye Pharma (USA) Ltd. | 1 | $29 |
| Alkermes, Inc. | 1 | $24 |
Products named: COBENFY, INGREZZA, INVEGA SUSTENNA, SUBLOCADE, ABILIFY MAINTENA, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE, ARISTADA.
Industry payments across MD — which companies pay providers there.
